Abstract -Although VEGF (vascular endothelial growth factor) inhibitors (VEGFIs), are effective anticancer therapies, they cause hypertension through unknown mechanisms. We questioned whether changes in vascular redox state may be important, because VEGF signaling involves nitric oxide (NO) and reactive oxygen species. Molecular mechanisms, including NOS, NADPH oxidase (Nox)-derived reactive oxygen species, antioxidant systems, and vasoconstrictor signaling pathways, were probed in human endothelial cells and vascular smooth muscle exposed to vatalanib, a VEGFI. Vascular functional effects of VEGFI were assessed ex vivo in mouse arteries. Cardiovascular and renal in vivo effects were studied in vatalanib-or gefitinib (EGFI [epidermal growth factor inhibitor])-treated mice. In endothelial cells, vatalanib decreased eNOS (Ser 1177 ) phosphorylation and reduced NO and H 2 O 2 production, responses associated with increased Nox-derived O 2 − and ONOO − formation. Inhibition of Nox1/4 (GKT137831) or Nox1 (NoxA1ds), prevented vatalanib-induced effects. Nrf-2 (nuclear factor erythroid 2-related factor 2) nuclear translocation and expression of Nrf-2-regulated antioxidant enzymes were variably downregulated by vatalanib. In human vascular smooth muscles, VEGFI increased Nox activity and stimulated Ca 2+ influx and MLC 20 phosphorylation. Acetylcholine-induced vasodilatation was impaired and U46619-induced vasoconstriction was enhanced by vatalanib, effects normalized by N-acetyl-cysteine and worsened by L-NAME. In vatalanib-, but not gefitinib-treated mice vasorelaxation was reduced and media:lumen ratio of mesenteric arteries was increased with associated increased cardiovascular and renal oxidative stress, decreased Nrf-2 activity and downregulation of antioxidant genes. We demonstrate that inhibition of VEGF signaling induces vascular dysfunction through redox-sensitive processes. Our findings identify Noxs and antioxidant enzymes as novel targets underling VEGFI-induced vascular dysfunction. These molecular processes may contribute to vascular toxicity and hypertension in VEGFI-treated patients. (Hypertension. 2018;71:638-647.
A ngiogenesis, the formation of new blood vessels from preexisting vasculature, is critical in solid tumor growth and metastasis. This process is regulated by growth factors of which VEGF (vascular endothelial growth factor) plays a key role through effects on endothelial cell (EC) and vascular smooth muscle cell (VSMC) function. 1 The VEGF gene undergoes alternative splicing to form 6 isoforms, of which VEGF-A is the most biologically active. 2, 3 VEGF-A binds to 2 receptor tyrosine kinases, VEGFR-1 (Flt-1) and VEGF receptor-2 (VEGFR-2 or Flk-1) and a nontyrosine kinase, neuropilin (NRP; NRP1 and NRP2). However, VEGFR-2 is the primary receptor through which VEGF signals to regulate angiogenesis and endothelial function. 2, 4 Binding to VEGFR-2 initiates a tyrosine kinase signaling cascade that promotes vasodilatation via nitric oxide (NO) and prostacyclins, cell proliferation/survival, migration and differentiation into mature blood vessels. 5, 6 Inhibition of angiogenesis, by targeting VEGF signaling, has revolutionized cancer therapy with improved outcomes in some previously untreatable cancers. However, clinical observations unexpectedly showed that VEGF inhibition (VEGFI) was associated with cardiovascular toxicity, especially hypertension. 7, 8 The magnitude of VEGFI-induced hypertension is significant, with almost every clinical trial of VEGF inhibitors (VEGFIs) reporting an increase in blood pressure (BP) as an adverse effect with 40% to 60% of patients developing hypertension often severe (>150/100 mm Hg) or hypertensive crisis. [9] [10] [11] [12] Hypertension develops acutely, within 24 hours of starting treatment, and by 6 days it is sustained. 13 On treatment cessation BP decreases. 9, 10, 14 The pathophysiology of VEGFI-induced hypertension is elusive, although endothelial dysfunction, vascular remodeling, and capillary rarefaction have been implicated. 2, 15 VEGF is a known vasodilator through its effects on NO and as such a potential consequence of VEGFI is reduced NO, impaired vasodilatation and increased vascular tone, important determinants of augmented vascular resistance and BP elevation. [16] [17] [18] However, clinical and experimental data are conflicting, with studies showing both increased and decreased eNOS activity and NO production. 16, 17 Additionally, recent findings demonstrated endothelial-independent processes are involved in VEGFI effects. 19 Increased levels of ET-1, activation of the renin-angiotensin system, EC apoptosis and rarefaction have also been implicated in VEGFI-induced hypertension. 17, 18 Oxidative stress may contribute to the development of hypertension during antiangiogenic therapy. 22, 23 VEGF also regulates expression and activity of antioxidant system, including superoxide dismutase (SOD) and Nrf-2 (nuclear factor erythroid 2-related factor 2), the master regulator of antioxidant enzyme transcription. 24, 25 Thus, in addition to VEGF inducing vasodilatation through NO, generation of H 2 O 2 through Nox4 and activation of antioxidants, may influence vasorelaxation. However, whether VEGFI impacts these redox-sensitive processes to modulate a hypertensive vascular phenotype with associated BP elevation is unclear. Here, we hypothesized that VEGFIs promote oxidative stress leading to impaired vasodilatation and hypercontractility, processes associated with BP elevation. Mechanisms underlying this may relate to Nox dysregulation, downregulation of Nrf-2-regulated antioxidant systems and altered Ca 2+ handling in vascular cells.
Methods
The authors declare that all supporting data are available within the online supplementary files (Methods in the online-only Data Supplement). All experimental protocols on mice were performed in accordance with the Ethical Principles in Animal Experimentation adopted by the West of Scotland Research Ethics Service and in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Studies at Sapienza University were conducted in accordance with the Italian Law on the Protection of Animals. Human VSMCs (hVSMCs) were isolated from surgical specimens and in accordance with protocols approved by the West of Scotland Research Ethics Service (WS/12/0294).
Experimental Models
Studies were performed at the cellular (human ECs, VSMCs), tissue (isolated mouse arteries), and whole-animal (VEGFI-treated mice) levels. We examined effects of a VEGFR inhibitor, vatalanib and in some experiments compared effects to gefitinib, an inhibitor of the EGFR (epidermal growth factor receptor). We used this comparator agent because VEGF and EGF signal through similar pathways, yet whereas VEGF inhibition causes hypertension, EGFR inhibition does not.
Cell Culture
Cell-based studies were performed in human aortic EC (HAEC) and primary culture VSMCs (hVSMC).
Mice

Ex Vivo Vascular Studies
In some experiments, mouse mesenteric arteries were isolated to assess vascular functional responses to vatalanib in the absence and presence of L-NAME (eNOS inhibitor) or N-acetyl-cysteine ([NAC] ROS scavenger).
In Vivo Studies
Three groups of male SV-129 mice were studied for 2 weeks (1) vehicle-treated group, (2) VEGFR inhibitor, vatalanib-treated group (Vat, 100 mg/Kg/d), and (3) EGFR inhibitor, gefitinib-treated group (Gef, 100 mg/Kg/d). ] i was measured by Cal-520 fluorescence. Nrf-2 activity was assessed by nuclear translocation and Keap-1 expression by immunoblotting. Antioxidant enzymes (catalase activity) and gene expression (SOD1, catalase, GPX1, HO1) were determined by activity assays and qPCR.
Experimental Protocols
Phosphorylation of eNOS and MLC 20 was determined by immunoblotting.
Vascular functional and structural properties were assessed by wire and pressure myography.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 3.0 (GraphPad Software Inc, San Diego, CA). Data are presented as means±SEM. Groups were compared using Student t test or 1-way ANOVA. Bonferroni or Tukey post-test were used as appropriate. Results of statistical tests with P<0.05 were considered significant.
Results
Vatalanib Influences ROS and NO Generation in Human ECs
Vatalanib increased NADPH-dependent O 2 − generation in HAECs, effects that were inhibited by GKT137831 and NoxA1dstat ( Figure 1A ). This was associated with increased p47phox membrane expression ( Figure 1B 
Vatalanib Increases ROS Generation and Modulates Procontractile Signaling in hVSMCs
Vatalanib increased O 2 − production and ONOO − levels in hVSMC ( Figure 1F ; Figure S1 ). Pretreatment with Nox1/4 inhibitors prevented vatalanib-induced ROS generation. VEGF inhibition induced a significant increase in Ca 2+ influx in hVSMCs, effects that were attenuated by NAC ( Figure 3E ). Vatalanib also influenced procontractile signaling pathways, by inducing phosphorylation of MLC 20 , critically involved in triggering vascular contraction ( Figure 3D ).
Vascular Dysfunction Induced by Vatalanib Is Mediated by NOS-and Redox-Sensitive Mechanisms
To evaluate whether vatalanib-induced effects observed at the cellular level have functional significance at the vascular level, we studied isolated mouse mesenteric resistance arteries by myography and exposed vessel segments to vatalanib in the absence and presence of NOS inhibitors and ROS scavengers.
As shown in Figure 3A , ACh induced almost 100% vasorelaxation in control vessels, whereas in vatalanib-treated vessels, ACh-mediated vasorelaxation was reduced, with arteries relaxing maximally ≈40%. These responses were worsened by L-NAME, a NOS inhibitor. In arteries pretreated with NAC, vatalanib-induced endothelial dysfunction was ameliorated ( Figure 3B ). Corroborating our findings in hVSMC, vatalanib amplified agonist (U46619)-induced vasoconstriction, an effect blocked by NAC ( Figure 3C ).
Systemic Oxidative Stress, Vascular Dysfunction, and Arterial Remodeling in Vatalanib-Treated Mice
To further explore whether vatalanib influences redox-sensitive processes and vascular function in vivo, we examined mice Vatalanib influences reactive oxygen species (ROS) and nitric oxide (NO) generation and modulates procontractile signaling in human vascular cells. A, Lucigenin-derived chemiluminescence was performed in human aortic endothelial cell (HAEC) stimulated with vehicle or vatalanib in the presence or absence of NoxA1ds or GKT137831. B, p47 phox membrane expression was assessed by Western blotting in HAEC in presence of vatalanib or vehicle. C, H 2 O 2 levels, measured by amplex red in HAEC exposed to vatalanib. D, NO levels were determined by DAF-FM in vatalanib-treated HAEC (5 min) in the presence or absence of GKT137831 or NoxA1ds (30 min). E, Nuclear accumulation of Nrf-2 (nuclear factor erythroid 2-related factor 2) was determined by ELISA in HAEC nuclear extracts. F, Lucigenin-derived chemiluminescence was performed in hVSMC (human vascular smooth muscle cells) stimulated with vehicle or vatalanib±NoxA1ds or GKT137831. Results from amplex red, lucigenin and DAF-FM assays were normalized by protein content. Results are means±SEM of 4 to 7 experiments. *P<0.05 vs control; #vs vatalanib. treated with vatalanib for 2 weeks, and compared effects to gefitinib, an EGFR inhibitor. At the doses used, mean BP was not significantly different in control (92.6±1.7 mm Hg), vatalanibtreated (91.2±1.8 mm Hg) and gefitinib-treated groups (88.0±2.5 mm Hg). Vatalanib increased systemic ROS generation, as indicated by elevated plasma TBARS (thiobarbituric acid reactive substances) levels in the vatalanib (9.0±2.0 µmol/L) versus vehicle (5.1±0.2 µmol/L) and gefitinib groups (5.2±0.5 µmol/L).
As shown in Figure 4A and Table S1 , ACh-induced maximal vasorelaxation and EC 50 of isolated small mesenteric arteries were blunted in vatalanib-but not gefitinib-treated mice. SNP-induced vasodilatation was not influenced by either agent ( Figure 4B ). Mesenteric arteries from vatalanib-treated mice also exhibited an increase in media-tolumen ratio indicating vascular remodeling ( Figure S3 ). Vatalanib had no effect on cross-sectional area ( Figure S3 ). Gefitinib did not significantly influence vascular function or structure.
Vatalanib Modulates Redox Signaling in Tissues From Mice
To determine whether VEGFIs influence redox status in cardiovascular and renal tissue, we assessed levels of H 2 O 2 , O 2 − , and ONOO − , catalase activity and expression of pro-oxidant oxidases and antioxidant enzymes in aorta, kidney, and heart in VEGFI-treated mice.
As shown in Figure 4 aortic and cardiac levels of H 2 O 2 were reduced, whereas ONOO − levels were increased. Catalase activity was increased in aorta in the vatalanib group. Gene expression of Nox1, but not Nox2 or Nox4, was significantly increased in the heart by vatalanib and gefitinib ( Figure  S4 ). Cardiac gene expression of antioxidant enzymes catalase and GPX1 was reduced in vatalanib-treated mice, without effect on SOD1 ( Figure S4 ).
NADPH-stimulated production of O 2 − and H 2 O 2 levels were augmented by vatalanib in kidneys ( Figure 5A and 5B). This was associated with decreased activity of renal catalase ( Figure 5C ) and downregulation of the master antioxidant transcription factor Nrf-2, indicated by decreased Nrf-2 nuclear translocation and increased cytosolic levels of the Nrf-2 repressor, Keap-1 ( Figure 5D and 5E). At the gene level, expression of antioxidant enzymes catalase and GPX1 ( Figure 5F ), but not SOD1, was reduced in treated mice ( Figure S5 ). Vatalanib decreased mRNA expression of Nox4, without effect on Nox1 and Nox2 ( Figure S5 ).
Discussion
Despite the antiangiogenic and anticancer benefits of VEGFIs in clinical medicine, these agents have potent vascular toxicities and are prohypertensive because of, as yet, unclear molecular mechanisms. Processes that have been implicated include reduced endothelial-derived NO production, increased ET-1 levels, activation of the renin-angiotensin system, EC apoptosis, and microvascular rarefaction. 16, 17, 26 Here, we advance the field by demonstrating an important role for oxidative stress. In particular, we show that vatalanib, a VEGFR inhibitor, increased vascular cell ROS production and ONOO − formation and decreased activation of the eNOS-NO pathway. These phenomena translated to endothelial dysfunction, vascular hypercontractility and cardiovascular and renal oxidative stress in VEGFI-treated mice. Potential mechanisms underlying these effects involve upregulation of Noxs, in an isoform-and tissue-specific manner, and downregulation of Nrf-2-regulated antioxidant genes.
Endothelial function and vascular integrity are regulated by VEGF/VEGFR, through multiple signaling pathways, including PI3K-NOS and protein tyrosine phosphatases, which are modulated by changes in redox state. In particular, VEGF-induced activation of NOS and protein tyrosine phosphatases is linked to a reduced oxidative milieu that maintains vascular health. 20, 21, 27, 28 In addition, signaling through VEGF protects cells from oxidative stress, in part through activation of Nrf-2-regulated antioxidant enzymes. 29, 30 Disruption of these protective systems by inhibiting VEGF signaling leads to oxidative stress and cell damage. We explored this concept in the context of VEGFI-induced vascular toxicity and investigated whether vatalanib, a VEGFR inhibitor, influences redox state in human endothelial and VSMCs. Because we were particularly interested in the direct cellular effects of VEGFI, recapitulating the clinical scenario of antiangiogenic therapy, our studies were conducted without adding exogenous VEGF.
Both ECs and VSMCs exhibited increased vatalanib-induced NADPH-stimulated O 2
− production, involving Nox1/Nox4. Because ROS generation was rapid, it is likely that constitutively functional Nox1/4 was modulated by vatalanib, which also had more long-term actions by regulating Nox gene expression in an isoform-specific manner. The acute effect may also relate to dampening of protective antioxidant systems by vatalanib, similar to what has been shown for other VEGFIs. 31, 32 In ECs, a consequence of increased O 2 − production is decreased eNOS-generated NO bioavailability and increased ONOO − formation, as we observed. These events, together with reduced generation of H 2 O 2 , which induces vasodilation and is vasoprotective, 33, 34 may underlie endothelial dysfunction and vascular oxidative damage by vatalanib. In support of our findings, others have shown that VEGFIs acutely increase ROS generation in retinal pigment epithelial cells, 29 increase oxidative cellular toxicity 35 and augment oxidative stress, inflammation and endothelial dysfunction in mouse lung and human lung microvascular ECs.
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Figure 4.
Vatalanib, but not gefitinib, impairs ACh-induced vasodilation and modulates redox signaling in aorta and heart from mice. Bar graphs represent the maximal response (E max ) of ACh (A) and SNP (B) in mesenteric arteries from mice treated with vatalanib (100 mg/Kg per d), gefitinib (100 mg/Kg per d), or vehicle assessed by wire myograph. H 2 O 2 levels were measured by amplex red assay in endothelium-intact aorta and heart (C) from vatalanib and gefitinib-treated mice. Nitrotyrosine was assessed as an index of peroxynitrite (ONOO − ) formation in aorta and heart (D) from treated mice. Catalase activity was performed in aorta and heart (E) by assay kit. Results were normalized by protein content. Results represent the mean±SEM of 5 to 7 experiments. *P<0.05 vs vehicle.
To investigate whether the findings observed at the cellular level translate to functional responses, we studied mouse vessels exposed to vatalanib ex vivo, and demonstrated significantly impaired endothelial function, responses that likely involve dysregulated eNOS and oxidative stress because L-NAME worsened vasorelaxation, whereas the ROS scavenger NAC, ameliorated endothelium-dependent vasorelaxation. Vatalanib also amplified agonist-stimulated vasoconstriction, possibly linked to increased [Ca 2+ ] i signaling and activation of contractile machinery, as evidenced by increased phosphorylation of MLC as we demonstrated in VSMCs. Because NAC normalized hypercontractile responses, redox-sensitive processes are likely also important in vatalanib vascular functional effects. In line with our findings, 4 multitargeted VEGFIs potently increased vasoconstriction in mice. 19 The findings in isolated arteries were recapitulated in in vivo studies in mice treated for 2 weeks with vatalanib, where endothelium-dependent vasorelaxation was attenuated with associated increased cardiovascular production of O 2 − and ONOO − and reduced generation of H 2 O 2 . Whereas O 2 − and ONOO − are associated with vasoconstriction and vascular injury, H 2 O 2 is vasoprotective acting as a vasodilator through protein kinase G (PKG). 33, 34, 37 Processes underlying these phenomena likely involve decreased eNOS/NO generation, Nox activation, increased catalase activity (which catalyzes the decomposition of H 2 O 2 to H 2 O and O 2 ) and reduced protective antioxidant systems, similar to what we observed in human vascular cells.
Whereas vatalanib reduced H 2 O 2 production in vessels, it increased production in kidneys, possibly because of reduced catalase activity. Renal oxidative stress was increased by vatalanib, with associated decreased activity of Nrf-2 as evidenced by decreased nuclear translocation and increased cytosolic content of the Nrf-2 repressor Keap-1. Loss of Nrf-2 activity, which regulates antioxidant genes, such as catalase and GPX1, likely dampens the antioxidant protective status, contributing to renal oxidative stress in vatalanib-treated mice. Interplay between VEGF, Nrf-2, and other antioxidant systems has been demonstrated 38, 39 and a VEGF-Nrf-2 positive feedback loop, which protects against oxidative stress, has been demonstrated in brain microvascular ECs 38 and in cancer cell lines. 30 Hence, disruption of this feedback loop with VEGFIs, would downregulate Nrf-2, similar to what we observed in our studies. Aggravation of renal damage by VEGFIs has also been shown in diabetic mice, processes attributed to oxidative stress and inactivation of the Akt/eNOS/NO axis. 39 To elucidate whether inhibition of VEGFR tyrosine kinases by vatalanib is a generalized or specific phenomenon, we also evaluated effects of gefitinib, which inhibits EGFR, in part, through common VEGFR signaling pathways. Our findings clearly demonstrate that vatalanib, but not gefitinib-induced vascular dysfunction and cardiovascular and renal oxidative stress, suggesting specific cardiovascular toxicity when VEGFR is targeted. Others have also shown differential effects of VEGFI and epidermal growth factor inhibitors. 28, 29 Mice treated with sunitinib, which primarily targets VEGFR tyrosine kinases, exhibited systolic dysfunction and metabolic abnormalities, which were absent in mice treated with the EGFRI erlotinib. 40 Using a nontargeted metabolomics approach, it was found that sunitinib, but not erlotinib, decreased docosahexaenoic acid, arachidonic acid/eicosapentaenoic acid, O-phosphocolamine, and 6-hydroxynicotinic acid, important anti-inflammatory mediators, and regulators of mitochondrial function. Loss of these compounds may underlie VEGFIinduced mitochondrial dysfunction, oxidative stress, and cardiovascular damage. 40 Despite the vascular dysfunction, arterial remodeling and significant cardiovascular and renal oxidative effects induced by vatalanib, mice did not develop hypertension. Reasons for this may relate to the low dose of vatalanib used and to the relatively short treatment period. In addition, we used tailcuff methodology to measure BP at 1 time point, and as such we may have missed subtle changes in BP, especially over the 24-hour period. Telemetry would have provided a better approach to fully characterize BP changes. Nevertheless, our data clearly demonstrate, that even at subpressor doses, vatalanib-induced cardiovascular and renal toxicity, which may be amplified with higher doses and more chronic treatment. 39 In conclusion, this study provides novel mechanistic insights to better understand the pathophysiology of VEGFIinduced vascular dysfunction and hypertension. In particular, we demonstrate at the cellular, vascular, and whole-animal levels, that vatalanib promotes oxidative stress, Nox dysregulation, and downregulation of Nrf-2-regulated antioxidant systems. Our study identifies redox-sensitive mechanisms whereby VEGF signaling inhibition may cause cardiovascular toxicity, as highlighted in Figure 6 . This study might be especially important to guide new therapeutic approaches to reduce cardiovascular risk without compromising anticancer benefit of VEGFIs. Such an approach may include strategies to reduce VEGFI-induced oxidative stress using adjuvant therapies such as Nrf-2 activators or Nox inhibitors. This concept awaits further confirmation.
Perspectives
Our results identify novel molecular mechanisms involving changes in redox state whereby VEGFI promotes vascular injury and dysfunction. Our data are of clinical significance because these processes may contribute to vascular toxicities associated with VEGFI-associated hypertension in patients treated with antiangiogenic therapy targeting VEGF signaling pathways. In particular, our findings that VEGFI-induced oxidative stress is linked to upregulation of vascular Noxs and dampening of antioxidant enzymes may direct future therapeutic approaches to reduce vascular toxicities caused by VEGFI anticancer drugs. For example, adjuvant therapy with Nrf-2 agonists may be an interesting approach, that might warrant further consideration. ] i and activation of MLC 20 , leading to enhanced vascular contraction. In ECs (right), vatalanib acts by increasing ROS production through Nox activation but also by downregulating the antioxidant system. In addition, vatalanib decreases the vasodilatory ROS, H 2 O 2 , as well as reduces eNOS phosphorylation and nitric oxide (NO) production in ECs, which may be culminating in endothelial dysfunction. The dysregulation of both VSMC and EC function induced by vatalanib may induce vascular tone alterations and vascular remodeling, and may explain, at least in part, molecular mechanisms underlying VEGF inhibitorassociated hypertension.
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